Vvital Biomed

Company Overview

Snapshot

Founded in December 2016 by Nir Golan and Aram K.Smolinsky, Vvital Biomed operates with 1–10 employees. The company secured one funding round from one investor. In January 2020, Vvital Biomed received funding from The Trendlines Group.

Business overview

Vvital Biomed is a Health Tech & Life Sciences company focused on developing a technology for transcatheter mitral valve repair (TMVR). Its core product, VLR, aims to provide a stable device solution that is less affected by systolic pressure load or annular dilatation, simplifying the TMVR procedure. The company operates in the medical devices, cardiology, and medical treatment & therapeutics sectors, serving healthcare providers globally.

Company Intelligence Q&A

What is Vvital Biomed's primary focus?

Vvital Biomed is developing a technology for transcatheter mitral valve repair (TMVR), aiming to create a stable device that simplifies the procedure by being less affected by systolic pressure load or annular dilatation.

When was Vvital Biomed founded?

Vvital Biomed was founded in December 2016.

Who are the founders of Vvital Biomed?

Nir Golan and Aram K.Smolinsky are the co-founders of Vvital Biomed.

What is the status of Vvital Biomed?

Vvital Biomed is currently non-active and ceased to operate in February 2022.

Which investor participated in Vvital Biomed's funding round?

In January 2020, The Trendlines Group invested in Vvital Biomed's funding round.